The poster from the SITC 2017 conference referenced in the previous message in this thread is posted here. Very encouraging data suggesting that BET inhibitors have much promise to enhance/extend the efficacy of various cancer immunotherapies. They presented on a similar theme last year (see this poster) on pre-clinical potential of ZEN-3694 enhancing the efficacy of immunotherapies, but this new data is actually from the current Phase 1 mCRPC trial patients.